文献速递炎症性肠病

炎症性肠病患者冠状动脉介入治疗后心血管事件风险增加:一项全国性匹配队列研究

Increased Risk of Cardiovascular Events After Coronary Interventions in Inflammatory Bowel Disease: A Nationwide Matched Cohort Study.
PubMed 文献 · Aliment Pharmacol Ther · 2025-04-29

这项全国性匹配队列研究纳入2012至2022年接受经皮冠状动脉介入治疗或冠状动脉旁路移植术的成人,将炎症性肠病患者按1:10倾向评分匹配至无炎症性肠病对照。中位随访3.5年后,炎症性肠病患者主要不良心血管事件发生率为49.4%(发生率96.5/10000人年),对照为40.3%(发生率68.9/10000人年),风险比1.37(95%CI 1.24-1.52)。

要点

  • 炎症性肠病患者冠状动脉介入治疗后主要不良心血管事件风险升高37%(HR 1.37,95%CI 1.24-1.52)。
  • 除卒中外,主要不良心血管事件各组分风险均升高,炎症性肠病亚型及血运重建方式间无差异。
  • 每36例炎症性肠病患者10年内额外发生1例主要不良心血管事件。

核心结论

  • 炎症性肠病患者冠状动脉介入治疗后主要不良心血管事件风险升高37%,提示需加强此类高危人群的心血管风险降低。

研究设计与样本

  • 全国性队列研究纳入2012至2022年接受经皮冠状动脉介入治疗或冠状动脉旁路移植术的成人,炎症性肠病患者按1:10倾向评分匹配至无炎症性肠病对照,共987例炎症性肠病患者和9571例匹配对照。

主要发现

  • 中位随访3.5年后,主要不良心血管事件在炎症性肠病患者中发生488例(49.4%,发生率96.5/10000人年),在匹配对照中发生3857例(40.3%,发生率68.9/10000人年),HR 1.37(95%CI 1.24-1.52)。
  • 每36例炎症性肠病患者10年内额外发生1例主要不良心血管事件。
  • 除卒中外,主要不良心血管事件各组分风险均升高;炎症性肠病亚型间及经皮冠状动脉介入治疗与冠状动脉旁路移植术间无差异。
  • 风险在老年人和择期介入治疗中最高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel diseases (IBD) have been associated with an increased long-term risk of coronary artery disease due to chronic systemic inflammation. AIM: To evaluate the risk of major adverse cardiovascular events (MACE) after coronary interventions. METHODS: In this nationwide cohort study of adults undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) (2012-2022), patients with IBD were propensity score-matched 1:10 to comparators without IBD. The primary outcome was MACE, a composite of acute myocardial infarction, stroke, hospitalisation for heart failure, or mortality. Secondary outcomes included each MACE component, 30-day all-cause readmission, revascularisation and in-hospital outcomes including intensive care unit admission and length of hospital stay. We calculated hazard ratios (HRs) and incidence rates (IRs) using Cox proportional hazards modelling. RESULTS: We included 987 patients with IBD and 9571 matched comparators. After a median follow-up of 3.5 years, MACE occurred in 488 patients with IBD (49.4%, IR: 96.5/10,000 person-years [PY]) and in 3857 matched comparators (40.3%, IR: 68.9/10,000 PY); HR 1.37 (95% CI, 1.24-1.52). This equates to one additional MACE for every 36 patients with IBD over 10 years. The risk of each MACE component was increased, except for stroke. There were no differences between IBD subtypes or coronary intervention (PCI vs. CABG). Risks were highest in older individuals and elective interventions. CONCLUSIONS: Patients with IBD were at 37% higher risk of MACE after coronary intervention, indicating a need for intensified cardiovascular risk reduction in these high-risk individuals.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ebrahimi R, Ebrahimi F, Niess JH, et al. Increased Risk of Cardiovascular Events After Coronary Interventions in Inflammatory Bowel Disease: A Nationwide Matched Cohort Study. Aliment Pharmacol Ther. 2025. PMID: 40298092. doi:10.1111/apt.70162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。